ETON CBO David Krempa sells 100,000 shares (79.8% of non-derivative holdings) across 5 transactions at blended $32.30; retains 25,249 shares and 256,491 option shares.
David Krempa, Chief Business Officer of Eton Pharmaceuticals, executed 5 separate sales totaling 100,000 shares for $3,229,923.24 between May 22–27, 2026, at prices ranging from $31.49 to $35.00, realizing a blended average price of $32.30. The sales reduced his non-derivative holdings by 79.8%, from 125,249 to 25,249 shares, though he retains 256,491 shares in employee stock options across five distinct option vehicles. The sales occurred while the stock was up 38.2% over the prior 30 days and 87.8% over 90 days, and the company reported annual revenue growth of 104.9% year-over-year despite negative full-year net income. The large share reduction warrants scrutiny given the magnitude and the company's still-unprofitable status despite strong top-line growth, particularly as derivative holdings remain material to the executive's total position.